Literature DB >> 16637920

Thymus and myasthenia gravis: antigen processing in the human thymus and the consequences for the generation of autoreactive T cells.

A Melms1, C Luther, C Stoeckle, S Pöschel, P Schroth, M Varga, W Wienhold, E Tolosa.   

Abstract

Peptides displayed by antigen presenting cells in the thymus shape the T cell repertoire. We investigated the antigen processing machinery of the MHC class II presentation pathway and describe the differential expression of lysosomal proteases in compartments of the thymus and the peripheral lymphoid tissue. Overexpression of certain proteases found in the thymus and thymoma associated with myasthenia gravis is likely to affect tolerance induction and may promote the generation autoreactive CD4(+) T helper cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16637920     DOI: 10.1111/j.1600-0404.2006.00636.x

Source DB:  PubMed          Journal:  Acta Neurol Scand Suppl        ISSN: 0065-1427


  4 in total

Review 1.  The etiology of paraneoplastic autoimmunity.

Authors:  Emanual Maverakis; Heidi Goodarzi; Lisa N Wehrli; Yoko Ono; Miki Shirakawa Garcia
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

2.  Analysis of serum miRNA profiles of myasthenia gravis patients.

Authors:  Gisela Nogales-Gadea; Alba Ramos-Fransi; Xavier Suárez-Calvet; Miquel Navas; Ricard Rojas-García; Jose Luis Mosquera; Jordi Díaz-Manera; Luis Querol; Eduard Gallardo; Isabel Illa
Journal:  PLoS One       Date:  2014-03-17       Impact factor: 3.240

Review 3.  Animal models of myasthenia gravis: utility and limitations.

Authors:  Renato Mantegazza; Chiara Cordiglieri; Alessandra Consonni; Fulvio Baggi
Journal:  Int J Gen Med       Date:  2016-03-04

4.  Human Leucocyte Antigen B50 Is Associated with Conversion to Generalized Myasthenia Gravis in Patients with Pure Ocular Onset.

Authors:  Bedile Irem Tiftikcioglu; Irem Fatma Uludag; Yasar Zorlu; İbrahim Pirim; Ufuk Sener; Figen Tokucoglu; Meltem Korucuk
Journal:  Med Princ Pract       Date:  2016-10-31       Impact factor: 1.927

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.